2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2004080634v1 16/10/3081    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Strippoli, G. F.M. Articles by Craig, J. C. Search for Related Content PubMed PubMed Citation Articles by Strippoli, G. F.M. Articles by Craig, J. C.

Antihypertensive Agents for Primary Prevention of Diabetic Nephropathy

Centre for Kidney Research, Cochrane Renal Group, The Children’s Hospital at Westmead, School of Public Health, University of Sydney, Sydney, Australia

Address correspondence to: Dr. Giovanni F.M. Strippoli, Editor and Regional Coordinator of the Cochrane Renal Group, Centre for Kidney Research, Locked Bag 4001, Children’s Hospital at Westmead, Westmead, NSW 2145, Australia. Phone: +39-349-5705884; Fax: +39-080-5580776; E-mail: gfmstrippoli{at}aliceposta.it

Received for publication August 3, 2004. Accepted for publication July 8, 2005.

The objective of this study was to evaluate the comparative effects of antihypertensive agents in patients with diabetes and normoalbuminuria. Randomized, controlled trials that compared any antihypertensive agent with placebo or another agent in hypertensive or normotensive patients with diabetes and normoalbuminuria (albumin excretion rate <30 mg/d) were identified on Medline, in Embase, on the Cochrane Controlled Trials Register, in conference proceedings, and by contacting investigators. Two authors independently extracted data on renal outcomes and other patient-relevant outcomes (e.g., mortality, serious cardiovascular events) and assessed quality of trials. Analysis was by a random-effects model, and results were expressed as relative risk (RR) and 95% confidence intervals (CI). Sixteen trials (7603 patients) were identified, six of angiotensin-converting enzyme inhibitors (ACEi) versus placebo, six of ACEi versus calcium antagonists, one of ACEi versus calcium antagonists or combined ACEi and calcium antagonist, and three of ACEi versus other agents. Compared with placebo, ACEi significantly reduced the development of microalbuminuria (six trials, 3840 patients; RR 0.60; 95% CI 0.43 to 0.84) but not doubling of creatinine (three trials, 2683 patients; RR 0.81; 95% CI 0.24 to 2.71) or all-cause mortality (four trials, 3284 patients; RR 0.81; 95% CI 0.64 to 1.03). Compared with calcium antagonists, ACEi significantly reduced progression to microalbuminuria (four trials, 1210 patients; RR 0.58; 95% CI 0.40 to 0.84). A significant reduction in the risk for developing microalbuminuria in normoalbuminuric patients with diabetes has been demonstrated for ACEi only. It seems that the effect of ACEi is independent of baseline BP, renal function, and type of diabetes, but data are too sparse to be confident that these are not important effect modifiers, and an individual patient data meta-analysis is required.

This article has been cited by other articles:

				P. H. Gallego, M. E Craig, S. Hing, and K. C Donaghue Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes: prospective cohort study BMJ, August 26, 2008; 337(aug26_1): a918 - a918. [Abstract] [Full Text] [PDF]

				M. Mrkobrada, H. Thiessen-Philbrook, R. B. Haynes, A. V. Iansavichus, F. Rehman, and A. X. Garg Need for Quality Improvement in Renal Systematic Reviews Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1102 - 1114. [Abstract] [Full Text] [PDF]

				M. Buleon, J. Allard, A. Jaafar, F. Praddaude, Z. Dickson, M.-T. Ranera, C. Pecher, J.-P. Girolami, and I. Tack Pharmacological blockade of B2-kinin receptor reduces renal protective effect of angiotensin-converting enzyme inhibition in db/db mice model Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1249 - F1256. [Abstract] [Full Text] [PDF]

				P. Ruggenenti, A. Perna, M. Ganeva, B. Ene-Iordache, G. Remuzzi, and for the BENEDICT Study Group Impact of Blood Pressure Control and Angiotensin-Converting Enzyme Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes: A Post Hoc Analysis of the BENEDICT Trial J. Am. Soc. Nephrol., December 1, 2006; 17(12): 3472 - 3481. [Abstract] [Full Text] [PDF]

				R. J. Glassock Prevention of Microalbuminuria in Type 2 Diabetes: Millimeters or Milligrams? J. Am. Soc. Nephrol., December 1, 2006; 17(12): 3276 - 3278. [Full Text] [PDF]

				P. A McFarlane Review: ACE inhibitors delay microalbuminuria in diabetes without nephropathy and reduce mortality in diabetic nephropathy Evid. Based Med., October 1, 2006; 11(5): 144 - 144. [Full Text] [PDF]

				J. P. Casas, A. D. Hingorani, R. J. MacAllister, and L. Smeeth Progression of renal disease--can we forget about inhibition of the renin-angiotensin system? Authors' reply Nephrol. Dial. Transplant., September 1, 2006; 21(9): 2352 - 2353. [Full Text] [PDF]

				J. F. E. Mann, W. M. McClellan, R. Kunz, and E. Ritz Progression of renal disease--can we forget about inhibition of the renin-angiotensin system? Nephrol. Dial. Transplant., September 1, 2006; 21(9): 2348 - 2351. [Full Text] [PDF]

				S. D. Navaneethan, M. Querques, C. Bonifati, and G. F. M. Strippoli Antihypertensive Agents in Patients With Diabetes: Trade-off Between Renal and Cardiovascular Protection. The Diabetes Educator, July 1, 2006; 32(4): 596 - 602. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673